Lethal privacy: Quantifying life years lost if the right to informational self-determination guides genetic screening for Lynch syndrome.


Journal

Health policy (Amsterdam, Netherlands)
ISSN: 1872-6054
Titre abrégé: Health Policy
Pays: Ireland
ID NLM: 8409431

Informations de publication

Date de publication:
10 2019
Historique:
received: 11 12 2018
revised: 19 08 2019
accepted: 20 08 2019
pubmed: 8 9 2019
medline: 15 9 2020
entrez: 8 9 2019
Statut: ppublish

Résumé

Genetic relatives of hereditary colorectal cancer patients with Lynch syndrome (LS) are at risk of cancer. Testing both colorectal cancer patients and relatives of mutation carriers for LS allows targeted prevention. However, this could mean disclosing sensitive health data to family members. In light of potential trade-offs between cost-effectiveness and patient privacy, this study investigates the implications of increasing test uptake in Germany. Out of 22 screening strategies for LS, the non-dominated and current German strategies were assessed from the perspective of the statutory health insurance. Life years gained by increased prevention were estimated with Markov models. The effects and implications of different test uptake rates in index patients and their relatives were investigated by scenario analysis. Privacy limitations could yield health gains of up to 2500 undiscounted life years for first-degree relatives of index patients and substantially improve cost-effectiveness. However, this approach may contradict the right to informational self-determination. This study demonstrates the effect higher LS test uptakes could have on the lives and rights of colorectal cancer patients and their relatives. It shows potential conflicts between the efficient use of health care resources on the one hand and reasonable consideration of patient autonomy on the other.

Identifiants

pubmed: 31492458
pii: S0168-8510(19)30205-2
doi: 10.1016/j.healthpol.2019.08.015
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1004-1010

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Fabia Gansen (F)

Department of Health Care Management, Institute of Public Health and Nursing Research, Health Sciences, University of Bremen, Bremen, Germany. Electronic address: gansen@ipp.uni-bremen.de.

Franziska Severin (F)

Institute for Health Economics and Health Care Management, Helmholtz Center München, German Research Center for Environmental Health, Neuherberg, Germany.

Sebastian Schleidgen (S)

Department of Nursing Science, University of Philosophy and Theology Vallendar, Vallendar, Germany.

Georg Marckmann (G)

Institute for Ethics, History and Theory of Medicine, Ludwig-Maximilians-University Munich, Germany.

Wolf Rogowski (W)

Department of Health Care Management, Institute of Public Health and Nursing Research, Health Sciences, University of Bremen, Bremen, Germany; Institute for Health Economics and Health Care Management, Helmholtz Center München, German Research Center for Environmental Health, Neuherberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH